Genedata enters into collaboration with Schering AG in Screening Data Analysis

13-Apr-2004

Genedata announced that they entered into a collaboration and licensing agreement with Schering AG for the Genedata Screener TM AssayAnalyzer software earlier this year. The software module is in productive use at Schering's Screening and Assay Development department. This agreement expands the established collaboration between Schering and Genedata in genomics-based drug discovery.

"Schering is an important new customer for our Screener software. Schering demonstrates how the Screener AssayAnalyzer module brings improvements in data quality and analysis efficiency to existing in-house systems, with which it integrates seamlessly. We are also pleased that Schering trusts in our software solutions and services, and has opted to expand into the screening area in addition to the long-standing Schering-Genedata relationship in the genomics domain," states Dr. Stephan Heyse, Project Manager for Screener. "Opening a growth perspective for screening data analysis with a professional software, keeping pace with the rapid progress in screening technology, providing qualified support and lowering maintenance costs were the main objectives. Genedata meets all of these demands."

Dr. Ulf Boemer, Head of Technology Development & HTS Infrastructure at Schering, says: "We assessed the market and evaluated commercial solutions for the analysis and quality assurance of screening data. We came to the conclusion that the Screener AssayAnalyzer software is functionally a complete application and provides the best value for our investment."

Screener AssayAnalyzer is specifically designed to assess and improve the quality of screening data as well as to routinely reduce analysis time. In addition, the software provides significant gains in productivity and hit quality for the overall screening process. Screener AssayAnalyzer is a module of the Genedata Screener system. Screener standardizes and optimizes the complete screening data analysis process - from primary high-throughput screening and secondary validation screening to compound profiling and lead optimization. Screener saves significant costs and resources in the downstream drug discovery process by reducing both false-positive and false-negative rates as well as performing routine, comprehensive compound assessment for early guidance in compound optimization.

https://www.bionity.com/en/news/36635/genedata-enters-into-collaboration-with-schering-ag-in-screening-data-analysis.html